DiaMedica Therapeutics is a clinical-stage biopharmaceutical company developing recombinant human tissue kallikrein-1 (KLK1) therapies. Its lead candidate, DM199 (rinvecalinase alfa), is being studied for acute ischemic stroke and other indications linked to impaired blood flow and organ protection. The approach targets the kallikrein-kinin system rather than conventional clot-busting or device-only stroke care. Customers, if approved, would primarily be hospitals and stroke treatment centers; the company currently has no commercial product revenue.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q2 2025 | 0 | — | -7.7 | — |
| Q3 2025 | 0 | — | -8.6 | — |
| Q4 2025 | 0 | — | -8.7 | — |
| Q1 2026 | 0 | — | -10 | — |
| Q2 2026 | 0 | — | -10.1 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: AgomAb Therapeutics NV (AGMB), Citi Trends, Inc. (CTRN), Value Line, Inc. (VALU), Cerence Inc. (CRNC), Tectonic Therapeutic, Inc. (TECX), AVITA Medical, Inc. (RCEL)